Thrivent Financial for Lutherans Sells 6,344 Shares of Cencora, Inc. (NYSE:COR)

Thrivent Financial for Lutherans decreased its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 5.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 104,155 shares of the company's stock after selling 6,344 shares during the quarter. Thrivent Financial for Lutherans owned 0.05% of Cencora worth $23,500,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Pacer Advisors Inc. boosted its holdings in shares of Cencora by 6,855.3% during the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock worth $464,874,000 after purchasing an additional 2,035,679 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Cencora during the 4th quarter valued at $322,460,000. Wellington Management Group LLP increased its stake in shares of Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock worth $1,168,927,000 after acquiring an additional 338,452 shares during the last quarter. Amundi raised its holdings in shares of Cencora by 30.8% during the fourth quarter. Amundi now owns 1,338,710 shares of the company's stock worth $318,385,000 after acquiring an additional 314,846 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in Cencora by 40.2% in the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock worth $243,173,000 after purchasing an additional 308,773 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Cencora Stock Performance

COR traded up $0.81 during midday trading on Tuesday, reaching $268.31. The company's stock had a trading volume of 1,448,886 shares, compared to its average volume of 1,377,743. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $271.08. The stock has a market cap of $52.03 billion, a P/E ratio of 38.17, a PEG ratio of 1.31 and a beta of 0.51. The company has a fifty day simple moving average of $251.24 and a 200 day simple moving average of $240.23. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.82%. Cencora's dividend payout ratio is 31.29%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Mizuho assumed coverage on Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective on the stock. Evercore ISI increased their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Wells Fargo & Company lifted their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Finally, StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $280.20.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now owns 51,070 shares in the company, valued at $13,022,850. This trade represents a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,970 shares of company stock worth $2,998,670. 10.80% of the stock is currently owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.